

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2012**

	Current Quarter Ended 31.12.2012 (Unaudited) RM'000	Corresponding Quarter Ended 31.12.2011 (Unaudited) RM'000	Current Year-To-Date Ended 31.12.2012 (Unaudited) RM'000	Corresponding Year-To-Date Ended 31.12.2011 (Audited) RM'000
Revenue	8,522	8,470	32,796	31,611
Operating profit	2,568	2,596	10,534	11,124
Operating expenses	(2,261)	(1,992)	(8,263)	(8,256)
Finance costs	(100)	(132)	(427)	(489)
Profit before taxation	207	472	1,844	2,379
Tax expense	31	(182)	(436)	(622)
Profit after taxation	238	290	1,408	1,757
Other comprehensive income, net of tax	(10)	(9)	(2)	(33)
Total comprehensive income	228	281	1,406	1,724
Profit after taxation attributable to Owners of the Company:	238	290	1,408	1,757
Total comprehensive income attributable to Owners of the Company:	228	281	1,406	1,724
Earnings per share (sen) attributable to Owners of the Company: - Basic	0.16	0.19	0.94	1.18

Note:-

The above condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT 31 DECEMBER 2012

	As At Current Year Quarter 31.12.2012 (Unaudited) RM'000	As At Financial Year End 31.12.2011 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	16,381	16,276
Product development expenditure	321	760
Goodwill	58	58
Quoted investments	-	5
	<u>16,760</u>	<u>17,099</u>
Current assets		
Inventories	9,244	9,557
Trade receivables	7,171	6,390
Other receivables, deposits and prepayments	407	730
Tax refundable	126	194
Fixed and short term deposits with licensed banks	2,286	3,289
Cash and bank balances with licensed banks and other financial institution	5,284	7,086
	<u>24,518</u>	<u>27,246</u>
TOTAL ASSETS	<u>41,278</u>	<u>44,345</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share premium	3,520	3,520
Treasury shares	(12)	-
Retained profits	16,818	16,305
Fair value reserve	-	*
Revaluation reserves	3,177	3,178
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(31)	(29)
	<u>30,014</u>	<u>29,516</u>
Non-current liabilities		
Deferred taxation	549	580
Hire purchase payables	84	218
Term loans	4,849	5,377
	<u>5,482</u>	<u>6,175</u>
Current Liabilities		
Trade payables	3,157	3,311
Bill payable	1,247	3,101
Other payables and accruals	715	1,575
Amount owing to directors	2	2
Hire purchase payables	134	135
Term loans	527	499
Provision for taxation	-	31
	<u>5,782</u>	<u>8,654</u>
TOTAL LIABILITIES	<u>11,264</u>	<u>14,829</u>
TOTAL EQUITY AND LIABILITIES	<u>41,278</u>	<u>44,345</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.20</u>	<u>0.20</u>

Note:-

* RM650

The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value and the issued paid up share capital of 149,330,500 shares (149,390,500 shares - 2011) excluding treasury shares.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2012**

	←			Non-distributable			→		Total Equity RM'000
	Share Capital RM'000	Share Premium RM'000	Treasury Shares RM'000	Fair Value Reserve RM'000	Revaluation Reserves RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Distributable Retained Profits RM'000	
12 months ended 31 December 2012 (Unaudited)									
Balance at 1 January 2012	14,939	3,520	-	*	3,178	(8,397)	(29)	16,305	29,516
Total comprehensive income for the financial year	-	-	-	**	-	-	(2)	1,408	1,406
Purchase of treasury shares	-	-	(12)	-	-	-	-	-	(12)
Realisation of revaluation reserve	-	-	-	-	(1)	-	-	1	-
Interim tax-exempt dividend	-	-	-	-	-	-	-	(896)	(896)
Balance at 31 December 2012	14,939	3,520	(12)	-	3,177	(8,397)	(31)	16,818	30,014
12 months ended 31 December 2011 (Audited)									
Balance at 1 January 2011	14,939	3,520	-	5	3,179	(8,397)	-	15,219	28,465
Total comprehensive income for the financial year	-	-	-	(4)	-	-	(29)	1,757	1,724
Realisation of revaluation reserve	-	-	-	-	(1)	-	-	1	-
Final tax-exempt dividend	-	-	-	-	-	-	-	(672)	(672)
Balance at 31 December 2011	14,939	3,520	-	*	3,178	(8,397)	(29)	16,305	29,516

Note:-

- * RM650
- ** (RM650)

The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2012

	Current Year To Date Ended 31.12.2012 (Unaudited) RM'000	Corresponding Year To Date Ended 31.12.2011 (Audited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	1,844	2,379
Adjustments for:-		
Amortisation of product development expenditure	249	249
Depreciation of property, plant and equipment	625	627
Interest expense	405	462
Inventories written off	166	260
Product development expenditure written off	190	-
Plant and equipment written off	3	-
Gain on disposal of plant and equipment	(1)	(107)
Gain on disposal of quoted shares	(2)	(11)
Interest income	(96)	(124)
Unrealised (gain)/loss on foreign exchange	(55)	138
Operating profit before working capital changes	<u>3,328</u>	<u>3,873</u>
Decrease in inventories	147	182
Increase in trade and other receivables	(460)	(624)
Decrease in trade and other payables	(2,810)	(785)
Cash from operations	<u>205</u>	<u>2,646</u>
Net tax paid	(430)	(647)
Interest paid	(407)	(459)
Net cash from/(for) operating activities	<u>(632)</u>	<u>1,540</u>
Cash flows from/(for) investing activities		
Interest received	96	124
Purchase of property, plant and equipment	(733)	(2,286)
Grants received on research and development cost	-	850
Proceeds from disposal of plant and equipment	1	113
Proceeds from disposal of quoted shares	6	18
Net cash for investing activities	<u>(630)</u>	<u>(1,181)</u>
Cash flows from/(for) financing activities		
Drawdown of term loans	-	665
Repayment of term loans	(498)	(325)
Repayment to directors	-	(31)
Repayment of hire purchase obligations	(135)	(99)
Payment of dividend	(896)	(1,569)
Share buy-back	(12)	-
Net cash for financing activities	<u>(1,541)</u>	<u>(1,359)</u>
Net decrease in cash and cash equivalents	(2,803)	(1,000)
Cash and cash equivalents at beginning of the financial year	10,375	11,400
Foreign exchange difference	(2)	(25)
Cash and cash equivalents at end of the financial year	<u>7,570</u>	<u>10,375</u>
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	2,286	3,289
Cash and bank balances with licensed banks and other financial institution	5,284	7,086
	<u>7,570</u>	<u>10,375</u>

Note:-

The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)
(Incorporated in Malaysia)

NOTES TO THE INTERIM STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2012

A. NOTES PURSUANT TO THE MALAYSIAN FINANCIAL REPORTING STANDARD 134 (MFRS 134): INTERIM FINANCIAL REPORTING

A1. Basis of reporting preparation

The unaudited interim financial statements have been prepared in accordance with the Malaysian Financial Reporting Standards ("MFRS") 134: "Interim Financial Reporting" issued by the Malaysian Accounting Standards Board ("MASB") and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market ("ACE LR"). The unaudited interim financial statements should be read in conjunction with the audited annual financial statements of the Group for the financial year ended 31-December 2011.

Since the previous annual audited financial statements as at 31 December 2011 were issued, the Group has adopted the MFRS framework MASB with effect from 1 January 2012. This MFRS framework was introduced by the MASB in order to fully converge Malaysia's existing Financial Reporting Standards ("FRS") with the International Accounting Standards Board. Whilst all FRSs issued under the previous FRS framework were equivalent to the MFRSs issued under the MFRS framework, there are some differences in relation to the transitional provisions and effective dates contained in certain of the FRSs.

The following MFRS, Amendments to MFRSs and IC Interpretation have been adopted by the Group during the current period:

IC Interpretation 19 Extinguishing Financial Liabilities with Equity Instruments
Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters (Amendment to MFRS 1)
Disclosures - Transfer of Financial Assets (Amendments to MFRS 7)

The adoption of IC Interpretation 19, Amendments to MFRS 1 and MFRS 7 above did not have any financial impact on the Group as they mainly help to clarify the requirements of or provide further explanations to existing MFRSs.

The following MFRSs, Amendments to MFRSs and IC Interpretation have been issued by MASB but not yet effective:

MFRSs, Amendments to MFRSs and IC Interpretation		Effective Date
MFRS 9	Financial Instruments	1 January 2015
MFRS 10	Consolidated Financial Statements	1 January 2013
MFRS 11	Joint Arrangements	1 January 2013
MFRS 12	Disclosure of Interests in Other Entities	1 January 2013
MFRS 13	Fair Value Measurement	1 January 2013

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

A1. Basis of reporting preparation (Cont'd)

MFRS 119	Employee Benefits	1 January 2013
MFRS 127	Separate Financial Statements	1 January 2013
MFRS 128	Investments in Associates and Joint Ventures	1 January 2013
Amendments to MFRS 1	Government Loans	1 January 2013
Amendments to MFRS 7	Disclosures - Offsetting Financial Assets and Financial Liabilities	1 January 2013
Amendments to MFRS 9	Mandatory Effective Date of MFRS 9 and Transition Disclosures	1 January 2015
Amendments to MFRS 10, MFRS 11 and MFRS 12	Transition Guidance	1 January 2013
Amendments to MFRS 132	Offsetting Financial Assets and Financial Liabilities	1 January 2014
IC Interpretation 20	Stripping Costs in the Production Phase of a Surface Mine	1 January 2013
Annual Improvements to MFRSs 2009 - 2011 Cycle		1 January 2013

The initial adoption of the above applicable MFRSs (and its consequential amendments) and IC Interpretation, is expected to have no material impact on the interim financial statements of the Group.

A2. Auditors' report on preceding annual financial statements

The audited financial statements of the Company and its subsidiaries for the FYE 31 December 2011 were not subjected to any qualification.

A3. Seasonal or cyclical factors

The principal business operations of the Group were not significantly affected by seasonal or cyclical factors during the current quarter under review.

A4. Items of unusual nature and amount

There were no items affecting assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence during the current quarter under review.

A5. Material changes in estimates

There were no material changes in estimates of amounts reported that will have a material effect in the current quarter under review.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

A6. Issuances, cancellations, repurchase, resale and repayments of debt and equity securities

There were no issuances, cancellations, resale and repayments of debt and equity securities during the current quarter under review. The Company repurchased 50,000 of its issued ordinary shares from the open market for a total consideration of RM10,073 at an average price of RM0.20 per share in the current quarter. The repurchase transaction was financed by internally generated funds. The shares repurchased are being held as treasury shares.

A7. Dividends paid

Interim tax-exempt dividend of RM0.006 per ordinary share of RM0.10 each, amounted to RM895,983 was paid on 24 December 2012.

A8. Segmental information

Segmental revenue on the basis of geographical market is as follows:

Geographical Market	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
Asia other than Malaysia	5,879	4,448
Middle East	182	872
Malaysia	26,678	26,291
Africa	57	-
Total	32,796	31,611

A9. Valuation of property, plant and equipment

The valuation of the Group's freehold lands and buildings has been brought forward without any amendments from the annual financial statements for the FYE 31 December 2011.

A10. Capital commitments

As at the end of reporting period, there were no outstanding capital commitments not provided for in the financial statements.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

A11. Material subsequent event

There were no material events subsequent to the end of the current quarter that have not been reflected in the financial statements, which are likely to substantially affect the current quarter results under review.

A12. Changes in the Composition of the Group

There were no changes in the composition of the Group in the current quarter under review.

A13. Contingent Liabilities

Save for the corporate guarantee granted by the Company in favour of financial institutions for Islamic banking facilities extended to a subsidiary amounting to **RM17,131,000**, neither the Company nor its subsidiaries have any contingent liabilities at the end of the reporting period, which upon becoming enforceable, may have a material effect on the financial position of the Group.

The corporate guarantee forms part of the securities for the following banking facilities made available to a subsidiary company.

Islamic Banking Facility	Corporate Guarantee RM'000	Limit RM'000	Outstanding Balance
			As At 31 December 2012 RM'000
Bank overdraft	500	500	-
Trade line	6,000	6,000	1,247
Term loans	10,631	6,465	5,376
Total	17,131	12,965	6,623

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B. ADDITIONAL INFORMATION REQUIRED UNDER THE ACE LR

B1. Review of performance of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 31 December 2012 RM'000	Corresponding Quarter Ended 31 December 2011 RM'000	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
Revenue	8,522	8,470	32,796	31,611
Profit before taxation ("PBT")	207	472	1,844	2,379

Group's revenue increased by 0.61% or RM52,000 in the fourth quarter compared with the corresponding quarter of previous year.

A decrease of 56.14% or RM265,000 in Group's PBT for the fourth quarter compared with the corresponding quarter of previous year.

For the year-to-date ended 31 December 2012, Group's revenue increased by 3.75% or RM1.19 million compared to previous year whereas PBT decreased by 22.49% or RM535,000. The decline in PBT was mainly due to higher product cost and the increase of lower margin product sales as well as the increase in operating expenses.

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date

Revenue	Current Quarter Ended 31 December 2012 RM'000	Corresponding Quarter Ended 31 December 2011 RM'000	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
Trading	4,196	4,843	16,396	16,228
Manufacturing	4,326	3,627	16,400	15,383
Total	8,522	8,470	32,796	31,611

Trading products sales decreased by 13.36% in the current quarter ended 31 December 2012 compared with the corresponding quarter previous year. This was mainly attributed to the decrease in the sales of companion animal, injectable and feed supplement products.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date (Cont'd)

For the year-to-date ended 31 December 2012, Group's trading products sales increased by 1.04% compared with the same period previous year. This was mainly due to higher sales volume of feed supplement and companion animal products despite lower sales volume of injectable products.

Manufacturing products recorded 19.27% increase in sales for the current quarter ended 31 December 2012 compared with the corresponding quarter previous year. This was attributed to the increase in the sales of feed supplement and premixes products.

For the year-to-date ended 31 December 2012, Group's manufacturing products sales increased by 6.61% compared with the same period previous year. This was mainly due to higher sales volume of premixes and feed supplement products.

B3. Profit before taxation

Profit before taxation is arrived at after crediting/(charging):

	Current Quarter Ended 31 December 2012 RM'000	Corresponding Quarter Ended 31 December 2011 RM'000	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
Interest income	24	24	96	124
Other income including investment income	-	-	-	-
Interest expense	(96)	(126)	(405)	(462)
Depreciation and Amortisation	(223)	(298)	(874)	(876)
Provision for and write off of receivables	-	-	-	-
Provision for and write off of inventories	(50)	-	(166)	(260)
Product development expenditure written off	(113)	-	(190)	-
Gain on disposal of quoted shares or plant and equipment	-	72	3	118
Impairment of assets	-	-	-	-
Gain/(loss) on foreign exchange				
- realised	97	7	123	330
- unrealised	(64)	(80)	55	(138)
Gain/(loss) on derivatives	-	-	-	-
Exceptional items	-	-	-	-

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

B4. Material changes in the Current Quarter's results compared to the results of the immediate Preceding Quarter

	Current Quarter Ended 31 December 2012 RM'000	Preceding Quarter Ended 31 September 2012 RM'000	Variance	
			RM'000	%
Revenue	8,522	8,174	348	4.26
PBT	207	684	(477)	(69.74)

The Group reported 4.26% increase in revenue for the fourth quarter ended 31 December 2012 compared with the preceding quarter ended 30 September 2012 mainly due to the increase in sales volume of water soluble products and premixes products despite companion animal products sales decreased.

Group's PBT decreased by 69.74% in the fourth quarter ended 31 December 2012 compared with the preceding quarter ended 30 September 2012. This was attributed to higher sales volume of lower margin products and higher operating expenses.

B5. Prospects

The Group is optimistic about the prospect in 2013 in view of the encouraging Orgacids sales performance in the overseas markets, which has shown a positive growth of 19.00% in 2012 as compared to 2011. For the local market, the Group will implement a more aggressive plan to expand the companion animal products business. The Group also intends to launch additional range of nutritional supplement products from Korea and pet food from Taiwan in the second quarter of this year.

B6. Profit forecast and profit guarantee

No profit forecast or profit guarantee has been issued by the Group for the current quarter under review.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

B7. Taxation

	Current Quarter Ended 31 December 2012 RM'000	Corresponding Quarter Ended 31 December 2011 RM'000	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
<u>Income tax expense</u>				
Current financial year	57	140	504	616
(Over)/underprovision in previous financial year	-	-	(38)	(50)
	<u>57</u>	<u>140</u>	<u>466</u>	<u>566</u>
<u>Deferred tax expense</u>				
Current financial year	(88)	42	(30)	56
(Over)/underprovision in previous financial year	-	-	-	-
	<u>(88)</u>	<u>42</u>	<u>(30)</u>	<u>56</u>
Tax expense	<u>(31)</u>	<u>182</u>	<u>436</u>	<u>622</u>

The Company's wholly-owned subsidiary, Sunzen LifeSciences Sdn. Bhd. was awarded the BioNexus status incentive under the Promotion of Investment Act, 1986 by the Ministry of Finance, with the recommendation made by Malaysian Biotechnology Corporation Sdn Bhd on 23 July 2007. Accordingly, the subsidiary is granted 100% tax exemption from the statutory income derived from the production of in-feed anti bacterial products and supplements for animal health products for a period of 10 years from 1 January 2010 to 31 December 2019.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B8. Status of Corporate Proposal

There was no other corporate proposal announced but not completed as at the date of this announcement.

Utilisation of IPO Proceeds

As at 31 December 2012, the status of utilisation of the gross proceeds of RM8 million raised from the public issue was as follows:

Purpose	Proposed utilisation RM'000	Actual utilisation RM'000	Intended timeframe for utilisation from the listing date* (Months)	Deviation		Explanation
				RM'000	%	
Research and development	4,770	4,091	36	-	-	Note ⁽¹⁾
Overseas expansion	1,000	1,000	48	-	-	-
Working capital	430	250	24	-	-	-
Estimated listing expenses	1,800	1,980	3	(180)	(10.00)	Note ⁽²⁾
Total	8,000	7,321				

Notes:

(1) Sunzen Biotech had announced to Bursa Securities on 3 October 2012 to further extend the utilisation period for the balance proceeds to 8 October 2013.

(2) The excess amount of listing expenses incurred during the implementation of Sunzen Biotech's listing exercise was adjusted to the Company's working capital.

* Sunzen Biotech was listed on 8 October 2008.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B9. Group borrowings and debt securities

The Group's borrowings as at 31 December 2012 were as follows:

	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Short-term borrowings:-</u>			
Bills payable	1,247	-	1,247
Hire purchases	134	-	134
Term loans	527	-	527
	1,908	-	1,908
	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Long-term borrowings:-</u>			
Hire purchases	84	-	84
Term loans	4,849	-	4,849
	4,933	-	4,933
Total	6,841	-	6,841

The above borrowings are denominated in Ringgit Malaysia.

B10. Material Litigation

As at the date of this announcement, neither the Company nor any of its subsidiaries is engaged in any material litigation and arbitration either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Directors are not aware of any proceedings pending or threatened or of any facts likely to give rise to any proceedings which might materially and adversely affect the financial position or business of the Company or its subsidiaries.

B11. Dividend declared or recommended

No dividend was declared during the quarter under review.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

B12. Earnings per share

Basic earnings per share is calculated by dividing the Group's profit after taxation attributable to owners of the Company for the period over the weighted average number of ordinary shares in issue excluding treasury shares during the financial year as follows:

	Current Quarter Ended 31 December 2012	Corresponding Quarter Ended 31 December 2011	Current Year-To-Date Ended 31 December 2012	Corresponding Year-To-Date Ended 31 December 2011
Group's profit after taxation attributable to owners of the Company (RM)	238,000	290,000	1,408,000	1,757,000
Weighted average number of ordinary shares in issue excluding treasury shares	149,330,500	149,390,500	149,330,500	149,390,500
Basic earnings per share (sen)	0.16	0.19	0.94	1.18

B13. Disclosure of Realised and Unrealised Profits or Losses

The breakdown of the retained profits of the Group at the end of the reporting period is presented in accordance with the directive issued by Bursa Securities and prepared in accordance with Guidance on Special Matter No. 1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Securities Listing Requirements, as issued by the Malaysian Institute of Accountants.

	Current Year-To-Date Ended 31 December 2012 RM'000	Corresponding Year-To-Date Ended 31 December 2011 RM'000
Total retained profits of the Group:-		
- Realised	17,345	16,916
- Unrealised	(527)	(611)
Total group retained profits as per consolidated financial statements	16,818	16,305

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

This quarterly report for the financial year ended 31 December 2012 has been seen and approved by the Board of Directors of Sunzen Biotech for release to Bursa Securities.

Date: 28 February 2013